Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12

[1]  I. Schmidt-Wolf,et al.  Activated T cells and cytokine-induced CD3+CD56+ killer cells , 1997, Annals of Hematology.

[2]  N. Yang,et al.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Huhn,et al.  Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. , 1996, Cellular immunology.

[4]  I. Weissman,et al.  Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. , 1995, Blood.

[5]  D. Huhn,et al.  Propagation of large numbers of cells of a human mixed‐lineage T‐lymphoid/myeloid , 1995, British journal of haematology.

[6]  M. Armant,et al.  IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. , 1995, Immunology.

[7]  E. Thiel,et al.  Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells. , 1993, Blood.

[8]  I. Weissman,et al.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.

[9]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[10]  D. Huhn,et al.  Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. , 1995, Bone marrow transplantation.